Low-pH Viral Inactivation Patents: Top Companies & Filing Trends 2026
Low-pH viral inactivation patents: who holds the ground in viral clearance processing
87.6% concentration. The top 5 of 11 ranked assignees hold 78 of the 89 records in scope — a field with almost no room left at the centre. Filings rose from 4 in 2017 to a peak of 12 in 2020, cooled, then rebuilt — 4 filings in 2021 to 8 in 2024, a +100% move over that three-year span. 2025 and 2026 figures (down to 1 by 2026) reflect publication lag, not a real slowdown.
- 1AMGEN INC56.2%
- 2ABBVIE INC12.4%
- 3ABBVIE BIOTHERAPEUTICS INC7.9%
- 4BRISTOL MYERS SQUIBB CO6.7%
- 5GENENTECH INC4.5%
See the full viral clearance processing — low-ph viral inactivation patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on low-pH viral inactivation?
One assignee holds 50 of the 89 records in scope, making it by far the largest filer in this dataset. The next four ranked assignees combine with the leader for 78 records, or 87.6% of everything in scope, and the remaining six ranked assignees account for the rest down to a single filing each. This is a concentrated field with one clearly dominant portfolio rather than several evenly matched competitors.
Is low-pH viral inactivation patent activity growing or slowing?
Filing rose from 4 records in 2021 to 8 in 2024, a growth of 100% over that three-year span, after an earlier peak of 12 filings in 2020. Counts for 2025 and 2026 appear lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. Read the 2024 figure as the most recent reliable year for trend comparison.
What technology areas overlap most with low-pH viral inactivation claims?
C07K (peptides and proteins) appears in 88.8% of the 89 records, meaning inactivation claims are almost always tied to a specific protein or antibody purification context. B01D (separation and filtration processes) appears in 51.7% and C12P (fermentation and enzymatic synthesis) in 46.1%, showing that inactivation is typically claimed together with the surrounding purification or fermentation hardware rather than as an isolated chemical step.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Viral Clearance Processing — Low-pH Viral Inactivation Patent Landscape covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.